FDA To Disclose More On Paragraph IV ANDA Filings
This article was originally published in The Tan Sheet
Executive Summary
FDA's posting of dates when Paragraph IV applications are filed will allow generic firms to assess whether they are eligible for the 180-day exclusivity and improve planning of their filings
You may also be interested in...
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer
Commit Lozenge Generic Equivalent Application Filed
A recent regulatory submission filed with FDA is seeking 180-day exclusivity for a generic version of nicotine replacement therapy lozenges
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC